Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri MAK02L14R

What does the research say about Lactobacillus reuteri MAK02L14R?

2 health outcomes synthesised

Lactobacillus reuteri MAK02L14R has been studied in 2 health outcomes based on research syntheses. The strongest evidence is for reduced hospitalization duration, with moderate evidence strength from 3 studies. The research primarily involves children with acute gastroenteritis and preterm neonates, though the studies used a different strain (DSM 17938) rather than the specified MAK02L14R.

Strongest evidence: The outcome with the highest evidence strength is Reduced Hospitalization Duration, rated as moderate. All 3 studies reported beneficial effects, but effect sizes were mixed—a large effect was observed in preterm neonates, while effects in children with acute gastroenteritis were small. No consistent dose data were reported.

Mixed or weaker evidence: Reduced Duration of Diarrhea has low evidence strength. Of 3 studies, 2 reported beneficial effects and 1 was neutral. Effect sizes ranged from small to large; the most recent meta-analysis found a small benefit (mean difference -0.87 days).

Effective dose patterns: No consistent effective dose was reported across the syntheses for either outcome. Doses were not consistently documented in the included studies.

Population insights: The research predominantly focuses on children with acute gastroenteritis for both outcomes. Preterm neonates were studied only for hospitalization duration.

Notable caveats: Both syntheses note that the studies used strains L. reuteri DSM 17938 or ATCC 55730, not MAK02L14R, making applicability uncertain. The evidence base is small (3 studies per outcome), and publication bias is a concern due to the prevalence of positive findings.

Frequently asked

  • What is Lactobacillus reuteri MAK02L14R good for according to research?
    Research syntheses suggest it may help reduce hospitalization duration and shorten diarrhea duration in children with acute gastroenteritis. All 3 studies on hospitalization showed benefit, while 2 of 3 studies on diarrhea duration were beneficial. However, these findings are based on other strains of L. reuteri and may not directly apply to MAK02L14R.
  • What dose of Lactobacillus reuteri MAK02L14R is typically used in studies?
    Dose information was not consistently reported in the included studies. No specific dose range can be identified from the available syntheses for either hospitalization duration or diarrhea duration.
  • Who benefits most from Lactobacillus reuteri MAK02L14R?
    The research primarily involves children with acute gastroenteritis. For hospitalization duration, preterm neonates showed a large effect, while children with acute gastroenteritis had only small effects. For diarrhea duration, the evidence is limited to clinical pediatric populations.
  • Are there caveats or limitations in the research on Lactobacillus reuteri MAK02L14R?
    Yes. The evidence base is small (only 3 studies per outcome), and all studies used strains DSM 17938 or ATCC 55730, not MAK02L14R—so applicability is uncertain. Effect sizes are mixed, and publication bias is a concern due to the high proportion of positive findings.
  • Does Lactobacillus reuteri MAK02L14R help reduce hospitalization duration?
    Evidence is moderate for a beneficial effect: all 3 studies reported reduced hospitalization duration. However, effect sizes varied from small (in children with acute gastroenteritis) to large (in preterm neonates). The evidence is based on other strains and should be considered preliminary.
  • Does Lactobacillus reuteri MAK02L14R help reduce diarrhea duration?
    Evidence is low: 2 of 3 studies reported benefit, while 1 found no effect. The most recent meta-analysis showed a small benefit (mean difference -0.87 days). Given the small number of studies and use of different strains, conclusions are uncertain.

Most-studied combinations with Lactobacillus reuteri MAK02L14R

most supplement research is combination research
  • Low evidence
    withLactobacillus reuteri UALre-16forReduced Hospitalization Duration· 3 studies

    Across 3 papers studying the combination of Lactobacillus reuteri MAK02L14R and Lactobacillus reuteri UALre-16 for reduced hospitalization duration, all reported beneficial effects, with 2 of 3 finding statistically significant reductions. Effect sizes were mixed, ranging from small reductions (−0.54 days) in children with acute gastroenteritis to large reductions (−10.77 days) in preterm neonates. These results are similar to the solo syntheses for both strains individually, but the combination evidence is limited by the fact that the studies labeled the intervention generically as 'L. reuteri DSM 17938', making it impossible to attribute effects to the specific combination of MAK02L14R and UALre-16 strains.

  • Daily Care Probiotic

    By Probulin

    4.7 (149 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $41.24
    		In
    Vitacost
    $50.29
    		In
    Vitamin Shoppe
    $-
    		Out

  • Total Care Soothe Probiotic + Prebiotic & Postbiotic

    By Probulin

    4.7 (25 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $35.99
    		In
    Vitacost
    $41.39
    		In
    Vitamin Shoppe
    $-
    		Out
Back to top